CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

Stock Information for Citius Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Citius Oncology Inc.

CNS Pharmaceuticals Reports Full Year 2024 Financial Results
CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme
CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing
CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum
CNS Pharmaceuticals, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference
CNS Pharmaceuticals Announces Reverse Stock Split
CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit
CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.